Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36970| Title: | Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma. | Authors: | Grigoriadis G. ;Fedele P.L. ;Chee A.;Low M.S.;Vilcassim S.;Gregory G.P.;Gilbertson M. ;Ratnasingam S. | Institution: | (Chee, Low, Vilcassim, Gregory, Gilbertson, Ratnasingam, Grigoriadis, Fedele) Monash Haematology, Monash Health, Clayton, Australia (Low, Fedele) Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (Vilcassim, Gregory, Grigoriadis) School of Clinical Sciences at Monash Health, Monash University, Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia | Issue Date: | 31-Aug-2018 | Copyright year: | 2018 | Publisher: | Blackwell Publishing Ltd | Place of publication: | United Kingdom | Publication information: | British Journal of Haematology. 182 (5) (pp 739-741), 2018. Date of Publication: September 2018. | Journal: | British Journal of Haematology | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/bjh.14871 | ORCID: | Chee, Adrian; ORCID: http://orcid.org/0000-0001-6602-6447 | Link to associated publication: | Click here for full text options | PubMed URL: | 28857117 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28857117] | ISSN: | 0007-1048 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/36970 | Type: | Letter | Subjects: | immunomodulating agent/dt [Drug Therapy] autologous stem cell transplantation cancer combination chemotherapy cancer staging *cancer survival clinical effectiveness cost effectiveness analysis drug efficacy *drug response human letter multiple cycle treatment *multiple myeloma/dt [Drug Therapy] *multiple myeloma/th [Therapy] outcome assessment overall survival priority journal survival analysis survival rate survival time bortezomib/cb [Drug Combination] bortezomib/dt [Drug Therapy] bortezomib/sc [Subcutaneous Drug Administration] cyclophosphamide/cb [Drug Combination] cyclophosphamide/dt [Drug Therapy] dexamethasone/cb [Drug Combination] dexamethasone/dt [Drug Therapy] proteasome inhibitor/dt [Drug Therapy] overall survival priority journal survival analysis survival rate survival time outcome assessment *multiple myeloma / *drug therapy / *therapy multiple cycle treatment Letter *drug response drug efficacy cost effectiveness analysis autologous stem cell transplantation cancer combination chemotherapy cancer staging *cancer survival clinical effectiveness human |
Type of Clinical Study or Trial: | Opinion, perspective or news |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.